Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Desmoglein 2 (DSG2) is a transmembrane cadherin-family protein that acts as a cell surface receptor and mediates strong cell–cell adhesion in epithelial tissue. It serves as the primary high-affinity entry receptor for adenovirus type 3 and other species B adenoviruses. Its extracellular cadherin domain 3 (EC3) is critical for virus binding, with an unusual 1:1 stoichiometry (one DSG2 per trimeric fiber knob), distinguishing it from other adenovirus–receptor interactions[1][2]. DSG2 is aberrantly expressed in some cancers and is being exploited for adenovirus-based targeted gene therapy.
For adenovirus-based therapies: Viral vector binds DSG2, mediating entry into cancer cells expressing DSG2. Use in oncolytic virotherapy and gene delivery approaches.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Desmoglein 2 receptor (DSG2).